Cooley advised Redx Pharma, a U.K. based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, on its agreement to be acquired by Skye Bioscience, a clinical-stage biotechnology company.
In connection with the transaction, Cooley also advised Redx Pharma on concurrent aggregate financings of approximately $125 million committed by a syndicate of new and existing leading healthcare institutional investors.
Redx Pharma to Be Acquired by Skye Bioscience, Concurrent $125 Million in Financings